Xtant Medical Holdings, Inc.
HealthcareAMEX:XTNT · New York Stock Exchange American
+$0.01 today
Vol 0.06M · Avg 0.16M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
9.8%
avg 36.6%
ROIC
6.5%
avg -23.2%
ROA
5.3%
avg -26.0%
Analysis
ROE is currently the strongest return metric at 9.8% versus its period average of 36.6%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sean E. Browne | President, Chief Executive Officer & Director | $762,864.00 | — | 59 | $2.58M | 1.84% |
Mark Schallenberger | Chief Operations Officer | $674,811.00 | — | 39 | $663,157.00 | 0.47% |
Scott C. Neils | Chief Financial Officer | $546,828.00 | — | 41 | $843,381.00 | 0.60% |
Catherine Lundy | Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A0 analysts |
| Revenue | N/A | N/A | +21.6% | +6.2% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +21.6% over three years. Forward estimates point to Revenue at +6.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Apyx Medical Corporation
NASDAQ:APYX
$196.39M
Quipt Home Medical Corp.
QIPT
$162.30M
FONAR Corporation
NASDAQ:FONR
$117.76M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
AVITA Medical, Inc.
NASDAQ:RCEL
$97.14M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$79.77M
Vivani Medical, Inc.
NASDAQ:VANI
$64.99M
eXoZymes, Inc.
NASDAQ:EXOZ
$60.20M
Estrella Immunopharma, Inc.
ESLA
$45.62M
InspireMD, Inc.
NSPR
$34.19M
Who manages XTNT?
Xtant Medical Holdings, Inc. (XTNT) lists 4 active executives. The top listed executive is Mark Schallenberger, Chief Operations Officer.
Are XTNT insiders buying or selling?
Recent insider activity shows net buying of $297.63M.
Explore More
Continue the stock analysis
Jump to another research area for this company.